Moderna stock tanks on COVID vaccine delivery slowdown

Due to the delays and prioritization of low-income countries, Moderna anticipates fiscal year 2021 product sales between $15B and $18B, down from previous guidance of $20 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.